A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma (SUMMIT-1)

This study has been terminated.
(More possibly-related deaths on tasisulam arm; failed to pass futility hurdle)
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01006252
First received: October 30, 2009
Last updated: August 9, 2011
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 9, 2011